Project description DEENESFRITPL Determining zinc content in cancer with MRI Prompt diagnosis and therapies for pancreatic cancer are limited, leading to a dismal prognosis and low survival rate. Emerging evidence indicates that pancreatic cancer cells present low levels of zinc importers and zinc content, while treatment with the zinc ionophore clioquinol inhibits tumour growth. The EU-funded tZR-CA-InVivo project aims to develop a magnetic resonance imaging tool, namely a zinc-responsive contrast agent to quantify zinc content in tissues. The contrasting agent will be designed to specifically target the tumour and provide a means for monitoring zinc levels in patients with cancer and evaluate the need to increase it. Show the project objective Hide the project objective Objective Pancreatic cancer has the lowest survival rate Pancreatic cancer has the lowest survival rate of all cancers in Europe, the median survival time is only a few months due to the lack of test for early diagnosis, and no effective therapies for metastatic forms. Pancreatic Ductal Adenocarcinoma (PDAC), like prostate and hepatocellular cancers present a down regulation of zinc importers and low zinc content. Treatment with clioquinol, a zinc ionophore, to increase the amount of zinc in the tumor has shown to inhibit tumor growth. This project aims at creating new tool to better detect PDAC by Magnetic Resonance Imaging, and the evaluation of di zinc ionophore to elevate the content in zinc in the tumor environment. Using the same modular approach, a normal and a zinc responsive contrast agent targeted to the PDAC will be synthesized by conjugation of a peptidic sequence known to target the tumor bearing a Single Core Multimodal Imaging Platform for quantification, with a peptide functionalized with a normal or zinc responsive contrast agent. After careful characterizations in vitro and ex vivo, they will be used in mice implanted with orthoptic pancreatic tumors. One of the projects developed by the “Metallic complexes for MRI” group, consist designing and using MRI probe for various substrates, including zinc. The group masters all the techniques to characterize the contrast agents, and the experience researcher (ER) will bring the knowledge about zinc biology, and infrared microscopy to quantify the contrast agent in tissues. Benefiting from the competitive interdisciplinary environment of CBM, and within the group, the ER will acquire new technical skills, knowledge and network the frontier between chemistry, biology and MRI imaging, in particular working with animal model (mice), to adequately implement the project and complete her skill set to become an independent researcher interested in developing tools to study the role of metals in biological context. Fields of science medical and health sciencesclinical medicineoncologyprostate cancernatural scienceschemical sciencesinorganic chemistrytransition metalsnatural sciencesbiological sciencesbiochemistrybiomoleculesengineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imagingmedical and health sciencesclinical medicineoncologypancreatic cancer Keywords MRI zinc responsive probe Peptide PDAC Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2019 - Individual Fellowships Call for proposal H2020-MSCA-IF-2019 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS Net EU contribution € 196 707,84 Address RUE MICHEL ANGE 3 75794 Paris France See on map Region Ile-de-France Ile-de-France Paris Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 196 707,84
